# A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

> **NCT01636960** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 9 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** PegIFN alfa-2b

## Key facts

- **NCT ID:** NCT01636960
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-25
- **Primary completion:** 2014-03-26
- **Final completion:** 2015-11-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636960, "A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01636960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*